Go Pro
OTCMKTS:SEOVF

Sernova Biotherapeutics Q4 2024 Earnings Report

Sernova Biotherapeutics logo
$0.06 +0.00 (+3.06%)
As of 03:54 PM Eastern

Sernova Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sernova Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Biotherapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Sernova Biotherapeutics Earnings Headlines

Sernova Biotherapeutics Inc SEOVF
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
See More Sernova Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova Biotherapeutics and other key companies, straight to your email.

About Sernova Biotherapeutics

Sernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical-stage biotechnology company focused on developing regenerative medicine technologies for the treatment of chronic diseases. Its platform combines an implantable device, therapeutic cells and methods intended to protect transplanted cells from immune-system rejection.

The company’s primary technology is the Cell Pouch System, an implantable, vascularized device designed to house therapeutic cells and support their long-term function in the body. Sernova has investigated the platform for conditions including type 1 diabetes and hemophilia, with research involving insulin-producing islet cells and other cell-based therapies.

Sernova is based in London, Ontario, Canada, and has conducted research and clinical development activities in collaboration with academic and medical institutions. The company has been led by Philip Toleikis, who serves as president and chief executive officer. Its programs remain focused on advancing cell-based treatments toward potential clinical use.

View Sernova Biotherapeutics Profile